T1	Premise 43 305	16-year-old woman diagnosed with allergic rhinoconjunctivitis due to sensitization to grass pollens since she was 10 years old, who does not fully control the symptomatology during the pollination season with oral antihistamines and nasal topical corticosteroids
T2	Claim 365 455	Specific immunotherapy by sublingual or subcutaneous route for a minimum period of 3 years
T3	Claim 460 549	Specific immunotherapy by sublingual or subcutaneous route for a maximum period of 1 year
T4	Claim 554 610	Omalizumab subcutaneously every 4 weeks for up to 1 year
T5	Claim 615 687	Omalizumab subcutaneously every 4 weeks for a minimum period of 6 months
T6	Claim 714 887	Currently the only effective treatment capable of modifying the natural course of respiratory allergy is specific allergen immunotherapy for a minimum of 3 consecutive years
T7	Premise 889 946	In this patient the conventional treatment has not worked
T8	Claim 951 1012	it is possible to escalate to specific allergen immunotherapy
T9	Marker 948 950	so
R1	Support Ent1:T7 Ent2:T8	
R2	Support Ent1:T6 Ent2:T2	
R3	Support Ent1:T8 Ent2:T2	
T10	Claim 1014 1185	It is true that it is not necessary to wait 10 years to start it since it is indicated and its use is allowed if there is clinical relevance in patients older than 5 years
T11	Marker 1079 1084	since
T12	Claim 1187 1330	Omalizumab is a biological treatment that would only be indicated in cases of severe moderate bronchial asthma secondary to respiratory allergy
R4	Attack Ent1:T1 Ent2:T12	
R5	Attack Ent1:T12 Ent2:T4	
R6	Attack Ent1:T12 Ent2:T5	
T13	Treatment 365 455	Specific immunotherapy by sublingual or subcutaneous route for a minimum period of 3 years
T14	Treatment 460 549	Specific immunotherapy by sublingual or subcutaneous route for a maximum period of 1 year
T15	Treatment 554 610	Omalizumab subcutaneously every 4 weeks for up to 1 year
T16	Treatment 615 687	Omalizumab subcutaneously every 4 weeks for a minimum period of 6 months
